Inhibition of p 38 Mitogen-Activated Protein Kinase Improves Nitric Oxide

Kaisa M. Mäki-Petäjä, David J. Collier, John Morgan, Zixing Fang, Robert N. Willette, John J. Joseph Cheriyan, Andrew J. Webb, Lea Sarov-Blat, Maysoon Elkhawad, Sharon M.L. Wallace, Vasodilatation and Reduces Inflammation in Hypercholesterolemia Mediated − Inhibition of p38 Mitogen-Activated Protein Kinase Improves Nitric Oxide Print ISSN: 0009-7322. Online ISSN: 1524-4539 Copyright © 2011 American Heart Association, Inc. All rights reserved. is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231 Circulation doi: 10.1161/CIRCULATIONAHA.110.971986 2011;123:515-523; originally published online January 24, 2011; Circulation. http://circ.ahajournals.org/content/123/5/515 World Wide Web at: The online version of this article, along with updated information and services, is located on the http://circ.ahajournals.org/content/suppl/2011/01/20/CIRCULATIONAHA.110.971986.DC1.html Data Supplement (unedited) at:

[1]  N. Aiyar,et al.  Differential Effects of p38 Mitogen-Activated Protein Kinase and Cyclooxygenase 2 Inhibitors in a Model of Cardiovascular Disease , 2009, Journal of Pharmacology and Experimental Therapeutics.

[2]  Børge G Nordestgaard,et al.  Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial , 2009, The Lancet.

[3]  P. Vanhoutte,et al.  Endothelial dysfunction: the first step toward coronary arteriosclerosis. , 2009, Circulation journal : official journal of the Japanese Circulation Society.

[4]  H. Schnittler,et al.  Nox4 overexpression activates reactive oxygen species and p38 MAPK in human endothelial cells. , 2009, Biochemical and biophysical research communications.

[5]  Vilmundur Gudnason,et al.  Long-Term Interleukin-6 Levels and Subsequent Risk of Coronary Heart Disease: Two New Prospective Studies and a Systematic Review , 2008, PLoS medicine.

[6]  Peter Libby,et al.  Inflammation in Atherosclerosis : From Vascular Biology to Biomarker Discovery and Risk Prediction , 2007 .

[7]  M. Marber,et al.  Potential of p38-MAPK inhibitors in the treatment of ischaemic heart disease. , 2007, Pharmacology & therapeutics.

[8]  J. F. Schindler,et al.  p38 Pathway Kinases as Anti-inflammatory Drug Targets , 2007, Journal of dental research.

[9]  J. Stasch,et al.  Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. , 2006, The Journal of clinical investigation.

[10]  A. Tedgui,et al.  Cytokines in atherosclerosis: pathogenic and regulatory pathways. , 2006, Physiological reviews.

[11]  R. Mayer,et al.  p38 MAP kinase inhibitors: A future therapy for inflammatory diseases , 2006 .

[12]  L. Kuo,et al.  C-Reactive Protein Inhibits Endothelium-Dependent NO-Mediated Dilation in Coronary Arterioles by Activating p38 Kinase and NAD(P)H Oxidase , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[13]  M. Pfeffer,et al.  C-reactive protein levels and outcomes after statin therapy. , 2005, The New England journal of medicine.

[14]  François Mach,et al.  Inflammation and Atherosclerosis , 2004, Herz.

[15]  R. Rosenson.  Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. , 2004, Atherosclerosis.

[16]  I. Wilkinson,et al.  Infliximab Improves Endothelial Dysfunction in Systemic Vasculitis: A Model of Vascular Inflammation , 2004, Circulation.

[17]  D. Behm,et al.  p38 MAPK Inhibitors Ameliorate Target Organ Damage in Hypertension: Part 1. p38 MAPK-Dependent Endothelial Dysfunction and Hypertension , 2003, Journal of Pharmacology and Experimental Therapeutics.

[18]  S. Nerurkar,et al.  p38 MAPK Inhibitors Ameliorate Target Organ Damage in Hypertension: Part 2. Improved Renal Function as Assessed by Dynamic Contrast-Enhanced Magnetic Resonance Imaging , 2003, Journal of Pharmacology and Experimental Therapeutics.

[19]  J. Boehm,et al.  p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases , 2003, Nature Reviews Drug Discovery.

[20]  Daniel Steinberg,et al.  Atherogenesis in perspective: Hypercholesterolemia and inflammation as partners in crime , 2002, Nature Medicine.

[21]  M. Taskinen,et al.  Impaired Responsiveness to NO in Newly Diagnosed Patients With Rheumatoid Arthritis , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[22]  John C. Lee,et al.  Sustained activation of p38 mitogen-activated protein kinase contributes to the vascular response to injury. , 2002, The Journal of pharmacology and experimental therapeutics.

[23]  F. Ruschitzka,et al.  Anti–Tumor Necrosis Factor-&agr; Treatment Improves Endothelial Function in Patients With Rheumatoid Arthritis , 2002, Circulation.

[24]  D. Webb,et al.  Venous occlusion plethysmography in cardiovascular research: methodology and clinical applications. , 2001, British journal of clinical pharmacology.

[25]  John C. Lee,et al.  Hypertensive End-Organ Damage and Premature Mortality Are p38 Mitogen-Activated Protein Kinase–Dependent in a Rat Model of Cardiac Hypertrophy and Dysfunction , 2001, Circulation.

[26]  P. Libby,et al.  Endothelial function and coronary artery disease , 2001, Current opinion in lipidology.

[27]  J. Avruch,et al.  Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. , 2001, Physiological reviews.

[28]  Christopher K. Glass,et al.  Atherosclerosis The Road Ahead , 2001, Cell.

[29]  F. Perticone,et al.  Effects of atorvastatin and vitamin C on endothelial function of hypercholesterolemic patients. , 2000, Atherosclerosis.

[30]  D E Griswold,et al.  Inhibition of p38 MAP kinase as a therapeutic strategy. , 2000, Immunopharmacology.

[31]  A M Zeiher,et al.  Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. , 2000, Circulation.

[32]  Aroon D. Hingorani,et al.  Acute Systemic Inflammation Impairs Endothelium-Dependent Dilatation in Humans , 1999, Circulation.

[33]  A. Zeiher,et al.  Atherosclerosis-associated endothelial dysfunction , 2000, Zeitschrift für Kardiologie.

[34]  K. Williams,et al.  Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.

[35]  M. Taskinen,et al.  Impaired endothelium-dependent vasodilation in type 2 diabetes. Relation to LDL size, oxidized LDL, and antioxidants. , 1999, Diabetes care.

[36]  S. Kassis,et al.  p38 mitogen-activated protein kinase inhibitors--mechanisms and therapeutic potentials. , 1999, Pharmacology & therapeutics.

[37]  A. Dart,et al.  Endothelium-dependent relaxation by acetylcholine is impaired in hypertriglyceridemic humans with normal levels of plasma LDL cholesterol. , 1999, Journal of the American College of Cardiology.

[38]  D. Green,et al.  Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. , 1997, Circulation.

[39]  T. Imaizumi,et al.  Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. , 1997, Circulation.

[40]  M. Olschewski,et al.  Cigarette smoking potentiates endothelial dysfunction of forearm resistance vessels in patients with hypercholesterolemia. Role of oxidized LDL. , 1996, Circulation.

[41]  F. Mee,et al.  Evaluation of three devices for self-measurement of blood pressure according to the revised British Hypertension Society Protocol: the Omron HEM-705CP, Philips HP5332, and Nissei DS-175. , 1996, Blood pressure monitoring.

[42]  Michel Morange,et al.  A novel kinase cascade triggered by stress and heat shock that stimulates MAPKAP kinase-2 and phosphorylation of the small heat shock proteins , 1994, Cell.

[43]  J. Hsuan,et al.  Interleukin-1 activates a novel protein kinase cascade that results in the phosphorylation of hsp27 , 1994, Cell.

[44]  G. Watts,et al.  Impaired endothelium-dependent vasodilation of forearm resistance vessels in hypercholesterolaemia , 1992, The Lancet.

[45]  J. Cooke,et al.  L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. , 1992, The Journal of clinical investigation.

[46]  A. Quyyumi,et al.  Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. , 1990, The New England journal of medicine.

[47]  J. Loscalzo,et al.  Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. , 1990, The Journal of clinical investigation.

[48]  T. Matsubara,et al.  Increased superoxide anion release from human endothelial cells in response to cytokines. , 1986, Journal of immunology.